1st Quarter - Report

PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA

Firm
Client
Income
—
Expenses
$5,440,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

5 issue areas, each in the filer's own words, with who lobbied on it and where.

Trade (domestic/foreign) TRD

Biopharmaceutical innovation policy issues China intellectual property and market access issues India innovation, IP and market access issues International market access and intellectual property issues Issues related to PhRMAs Special 301 and National Trade Estimate (NTE) submissions including intellectual property and market access issues Transatlantic Trade and Investment Partnership (TTIP): Market access, intellectual property, regulatory and other issues including mutual recognition of inspections Trans-Pacific Partnership (TPP): Provisions related to intellectual property, market access and public health issues Trade Promotion Authority issues Turkey market access issues U.S.-Korea Free Trade Agreement: Implementation issues related to intellectual property and market access Canada intellectual property and market access issues

LobbyistCovered position, as disclosed
JOHN J CASTELLANI —
CHARLES M. CLAPTON —
CHESTER (CHIP) DAVIS —
JEFFREY FRANCER —
DAVID KORN —
COLLEEN MALONEY —
CARA MOON —
JENNIFER ROMANS —
NICK SHIPLEY —
JAMES M SPEARS —
SARAH AMY SPURGEON —
MATTHEW L SULKALA —
JAY TAYLOR New United States Trade Representative (USTR) - Associate General Counsel, Assistant General Counsel

Contacted: State, Dept of (DOS); HOUSE OF REPRESENTATIVES; SENATE; Health & Human Services, Dept of (HHS); U.S. Trade Representative (USTR); Patent & Trademark Office (PTO)

Health Issues HCR

S. 122: Safe and Affordable Drugs from Canada Act of 2015 - Provisions related to importation S. 289: American Cures Act - Provisions related to NIH funding S. 320: Medical Innovation Act of 2015 - Provisions related to NIH funding and covered manufacturer supplemental fees S. 337: FOIA Improvement Act of 2015 - Provisions related to the Freedom of Information Act (FOIA) S. 481: Improving Regulatory Transparency for New Medical Therapies Act - Provisions related to Drug Enforcement Administration (DEA) scheduling S. 483: Ensuring Patient Access and Effective Drug Enforcement Act of 2015 - Provisions related to registration under the Controlled Substances Act (CSA) S. 1128: Preserving Access to Orphan Drugs Act - Provisions related to orphan drug tax (113th Congress) H.R. 471: Ensuring Patient Access and Effective Drug Enforcement Act of 2015 - Provisions related to registration under the CSA H.R. 639: Improving Regulatory Transparency for New Medical Therapies Act - Provisions related to DEA scheduling H.R. 909: Andrea Sloan Compassionate Use Reform and Enhancement (CURE) Act - Provisions related to expanded access H.R. 1537: Advancing Hope Act of 2015 - Provisions related to making permanent pediatric rare disease voucher program Kids Count Act of 2015 (discussion draft) - Provisions for incentivizing pediatric rare disease drug development Food and Drug Administration Proposed rule: Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products (78 Fed. Reg. 67985) - Provisions related to product labeling changes and related procedures 21st Century Cures Act (discussion draft) - Provisions related to biopharmaceutical discovery, development, delivery and transparency Senate HELP Committee innovation agenda - Provisions related to biopharmaceutical discovery and development Implementation issues related to the Patient Protection and Affordable Care Act (PPACA) (Public Law 111-148), including health insurance exchanges Drug Supply Chain Security Act implementation issues Physician Payment Sunshine Act implementation issues, such as Open Payments System issues 340B Drug Discount Program issues General FDA advocacy Biopharmaceutical and medical innovation policy issues

Contacted: Health & Human Services, Dept of (HHS); Patent & Trademark Office (PTO); U.S. Trade Representative (USTR); State, Dept of (DOS); HOUSE OF REPRESENTATIVES; SENATE

Bills named: S. 1128 (114th), S. 122 (114th), S. 337 (114th), S. 483 (114th), H.R. 1537 (114th), H.R. 909 (114th), S. 289 (114th), H.R. 639 (114th), S. 481 (114th), S. 320 (114th), H.R. 471 (114th)

Budget/Appropriations BUD

Sen. Con. Res. 11: An original concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2016 and setting forth the appropriate budgetary levels for fiscal years 2017 through 2025 - Amendments related to the biopharmaceutical industry including compounding/right to try; patent litigation reform; and non-interference, among others H. Con. Res. 27: Establishing the budget for the United States Government for fiscal year 2016 and setting forth appropriate budgetary levels for fiscal years 2017 through 2025 - Issues related to the biopharmaceutical industry including Part D and National Institutes of Health (NIH) funding H.R. 1078: Food and Drug Administration Safety Over Sequestration Act of 2015 - Provisions related to exemption of certain user fees from sequestration

Contacted: Health & Human Services, Dept of (HHS); U.S. Trade Representative (USTR); SENATE; State, Dept of (DOS); Patent & Trademark Office (PTO); HOUSE OF REPRESENTATIVES

Bills named: H.Con.Res. 27 (114th), H.R. 1078 (114th)

Copyright/Patent/Trademark CPT

S. 131: Fair And Immediate Release of Generic Drugs Act (FAIR Generics Act) - Provisions related to patent settlements and patent enforcement S. 481: Improving Regulatory Transparency for New Medical Therapies Act - Provisions related to patent term restoration S. 632: Support Technology and Research for Our Nations Growth Patents Act of 2015 or STRONG Patents Act of 2015 - Provisions related to post-grant proceedings, bad faith demand letters, and PTO diversion H.R. 9: Innovation Act - Provisions related to patent litigation H.R. 406: Combination Drug Development Incentive Act of 2015 - Provisions related to exclusivity and clinical investigations essential to approval H.R. 639: Improving Regulatory Transparency for New Medical Therapies Act - Provisions related to patent term restoration H.R. 971: Orphan Product Extensions Now Accelerating Cures and Treatments Act of 2015 (OPEN Act) - Provisions related to extension of marketing exclusivity H.R. 1353: Promoting Access for Treatments Ideal in Enhancing New Therapies Act of 2015 or PATIENT Act of 2015 - Provisions related to extension of marketing exclusivity Draft legislation on demand letters, including Targeting Rogue and Opaque Letters (TROL) Act (113th Congress) Issues related to abuse deterrent exclusivity incentives Patent litigation reform issues Biopharmaceutical innovation and patent policy issues

Contacted: Patent & Trademark Office (PTO); State, Dept of (DOS); HOUSE OF REPRESENTATIVES; U.S. Trade Representative (USTR); Health & Human Services, Dept of (HHS); SENATE

Bills named: H.R. 1353 (114th), H.R. 9 (114th), S. 131 (114th), H.R. 639 (114th), H.R. 971 (114th), H.R. 406 (114th), S. 632 (114th), S. 481 (114th)

Medicare/Medicaid MMM

S. 31: Medicare Prescription Drug Price Negotiation Act of 2015 - Provisions related to Secretary negotiation authority in Part D program S. 141: Protecting Seniors' Access to Medicare Act of 2015 - Provisions related to Independent Payment Advisory Board (IPAB) repeal S. 648: Medicare Formulary Improvement Act - Provisions related to codification of six protected classes in Part D program S. 861: Preventing and Reducing Improper Medicare and Medicaid Expenditures Act of 2014 -Provisions related to anti-fraud proposals affecting federal programs H.R. 2: Medicare Access and CHIP Reauthorization Act of 2015 - Provisions related to Sustainable Growth Rate (SGR) reform and other Medicare, Medicaid, and CHIP amendments H.R. 1021: Protecting the Integrity of Medicare Act of 2015 - Provisions related to Part D lock-in program and other Medicare anti-fraud provisions H.R. 1190: Protecting Seniors' Access to Medicare Act of 2015 - Provisions related to IPAB repeal H.R. 1470: SGR Repeal and Medicare Provider Payment Modernization Act of 2015 - Provisions related to SGR reform and other Medicare, Medicaid, and CHIP amendments H.R. 3796: Comprehensive Care Payment Innovation Act - Provisions related to ensuring access to innovative treatments in delivery reform model (113th Congress) H.R. 4857: Ensuring Access to Treatment Act (discussion draft) - Provisions related to changes to Part B hospital outpatient drug payment policy (113th Congress) H.R. 5183: Value Based Insurance Design for Better Care Act of 2014 - Provisions related to changes to the Medicare Advantage Program (113th Congress) Hospital Improvements for Payment Act (discussion draft) - Provisions related to Medicare Parts A and B reform Cancer Care Payment Reform Act (discussion draft): Provisions related to oncology medical home demonstration Department of Health and Human Services (HHS) delivery system reform issues and regulatory barriers to innovation Medicare Part B Average Sales Price (ASP) issues Part D lock-in related legislation Medicare exclusion issues Medicare Part D rebates issues

Contacted: Patent & Trademark Office (PTO); SENATE; State, Dept of (DOS); HOUSE OF REPRESENTATIVES; U.S. Trade Representative (USTR); Health & Human Services, Dept of (HHS)

Bills named: S. 31 (114th), S. 141 (114th), H.R. 5183 (114th), S. 861 (114th), H.R. 1190 (114th), H.R. 1470 (114th), H.R. 3796 (114th), H.R. 4857 (114th), S. 648 (114th), H.R. 2 (114th), H.R. 1021 (114th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.